Volume 13, Number 2—February 2007
Subclinical Plasmodium falciparum Infection and HIV-1 Viral Load
Highlight and copy the desired format.
|EID||Brouwer KC, Mirel LB, Yang C, Lal RB, Kolczak MS, Van Eijk AM, et al. Subclinical Plasmodium falciparum Infection and HIV-1 Viral Load. Emerg Infect Dis. 2007;13(2):351. https://dx.doi.org/10.3201/eid1302.060573|
|AMA||Brouwer KC, Mirel LB, Yang C, et al. Subclinical Plasmodium falciparum Infection and HIV-1 Viral Load. Emerging Infectious Diseases. 2007;13(2):351. doi:10.3201/eid1302.060573.|
|APA||Brouwer, K. C., Mirel, L. B., Yang, C., Lal, R. B., Kolczak, M. S., Van Eijk, A. M....Lal, A. A. (2007). Subclinical Plasmodium falciparum Infection and HIV-1 Viral Load. Emerging Infectious Diseases, 13(2), 351. https://dx.doi.org/10.3201/eid1302.060573.|
To the Editor: Studies indicate that Plasmodium falciparum infection increases HIV replication in adults (1,2). Although malaria-related illness and death are more common in children, and HIV-1 generally progresses faster in children than in adults (3,4), to our knowledge the effect of intermittent malaria on HIV-1 viral load has not been directly explored in children. To investigate this issue, we monitored HIV-positive infants from a 1996–2001 birth cohort study in Kisumu, Kenya, a P. falciparum–holoendemic area.
Study design and methods have been described elsewhere (5,6). Twenty-four children that were perinatally infected with HIV were included in this substudy. During monthly visits during the child’s first 2 years of life, malaria and HIV incidence were recorded (5,6). Both children with malaria-positive blood smears and those with fever but no smear result available were treated with sulfadoxine-pyrimethamine according to national guidelines. At the time of this substudy, none of the study participants were taking antiretroviral drugs.
HIV and malaria diagnoses were determined by using standard methods (5–7). To reduce the chance of including infants infected through breast-feeding, perinatal infection was defined as >2 consecutive HIV-positive tests, with the first positive PCR results by 4 months of age (7). The so-called baseline viral load was the premalaria value measured 1 month before the first observation in the analysis. To be included in the analysis, follow-up visits had to have data available on the current and previous months’ viral load and malaria status and occur at roughly monthly intervals at >4 months of age.
Malaria parasites were found at 53 of 146 visits in the month before viral load measurement, although at 89% of visits in which children were malaria-positive, the children’s samples had <1,000 parasites/μL, and in only 13% of visits in which children had parasitemia did they also have fever (8). Median number of observations per child was 7 (range 2–18). No significant demographic or clinical differences were found between HIV-positive children in this substudy and those enrolled in the full cohort (data not shown).
Clinical and demographic variables were evaluated in univariate repeated measures analysis to determine associations with log-transformed HIV-1 viral load. Age and baseline viral load were strong predictors of current load (Table). Although not statistically significant, clearing the previous month’s malaria infection was associated with a drop in viral load (Table, p = 0.09). It was not possible to distinguish between the effects of treatment versus malaria clearance because 87% of malaria infections were treated with antimalarial drugs. However, viral load increased in those incorrectly treated for malaria presumptively (Table).
After adjusting for age and baseline viral load, we assessed log10 HIV viral load in relation to malaria clearance, persistence, absence, or new infection using a repeated measures model with autoregressive covariance structure. No differences were statistically significant, although clearing an infection versus no malaria had a 0.22 log viral load decrease (Table, p = 0.10). When 15 malaria episodes with malaria-free visits 1 month before and after the episode were compared, mean difference (signed-rank test) in viral load “before” and “after” malaria was not significant.
Our findings suggest that low-density malaria infection may not dramatically affect plasma HIV-1 levels in infants. This finding is similar to results of studies of perinatally HIV-infected children in which, although viral loads were unavailable, number of malaria episodes did not significantly affect development of AIDS-related symptoms (9,10). While clinical malaria leads to at least short-term HIV viral load increases in adults (1,2), the effect of subclinical malaria is unclear, and even less is known about coinfection in children. Children usually have higher baseline viral loads than adults; thus, the relative effect of malaria on viral load may not be as great. To reduce the impact of passively transferred maternal antibodies, analyses were done on visits after the child was 4 months old. However, lack of fully acquired antimalarial immunity may have led to different HIV/malaria interactions than seen in adults.
Viral load increased in infants that were incorrectly treated presumptively (due to fever) for malaria (Table). Most of these children were found to have other infections. Fever in malaria-endemic areas is often assumed to be malaria-related, but delay in treatment of nonmalarial infections may be harmful in HIV-infected children
Our assessment was limited in size and duration. Furthermore, in attempting to provide optimal patient care through conducting monthly surveillance and encouraging mothers to bring children in during febrile episodes, ability to assess the effect of high-density malaria was diminished because parasitemia levels never reached clinically significant levels. Finally, because malaria was diagnosed by microscopy, rather than PCR, some subclinical malaria infections may have been misclassified as malaria-negative.
Although we found no evidence of an association between subclinical, low-density malaria and infant HIV-1 viral load, the consequences of high-density or clinical malaria need to be explored. If clinical malaria in infants increases HIV-1 viral load as it does in adults (1,2), our study underscores dual benefits of malaria treatment in the context of HIV: 1) keeping malaria in check, and 2) preventing an increase in HIV viral load. Ethical issues prevent prospective studies to assess the impact of coinfection early in life, but alternatives include using animal models or stored specimens.
We are grateful to the Kenyan children who participated in this study and their families. We also thank the field and laboratory staff of the Centers for Disease Control and Prevention (CDC)/Kenya Medical Research Institute (KEMRI). We appreciate Davy Koech, director of KEMRI, for his support and approval with regard to publication of this article, and Feiko ter Kuile and Laurence Slutsker for their helpful comments.
This study was supported by AOT0483-PH1-2171 from the United States Agency for International Development. The Institutional Review Boards of CDC and KEMRI approved the methods.
- Hoffman IF, Jere CS, Taylor TE, Munthali P, Dyer JR, Wirima JJ, The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration.AIDS. 1999;13:487–94.
- Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N, Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study.Lancet. 2005;365:233–40.
- Rogers MF, Thomas PA, Starcher ET, Noa MC, Bush TJ, Jaffe HW. Acquired immunodeficiency syndrome in children: report of the Centers for Disease Control National Surveillance, 1982 to 1985.Pediatrics. 1987;79:1008–14.
- Pizzo PA, Wilfert CM. Markers and determinants of disease progression in children with HIV infection. The Pediatric AIDS Siena Workshop II.J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:30–44.
- Ayisi JG, van Eijk AM, ter Kuile FO, Kolczak MS, Otieno JA, Misore AO, Risk factors for HIV infection among asymptomatic pregnant women attending an antenatal clinic in western Kenya.Int J STD AIDS. 2000;11:393–401.
- Ayisi JG, van Eijk AM, Newman RD, ter Kuile FO, Shi YP, Yang C, Maternal malaria infection and perinatal HIV transmission, western Kenya.Emerg Infect Dis. 2004;10:643–52.
- Yang C, Li M, Newman RD, Shi YP, Ayisi J, van Eijk AM, Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission.AIDS. 2003;17:1667–74.
- Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, Oloo AJ, Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children.Am J Trop Med Hyg. 1999;60:641–8.
- Greenberg AE, Nsa W, Ryder RW, Medi M, Nzeza M, Kitadi N, Plasmodium falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children.N Engl J Med. 1991;325:105–9.
- Kalyesubula I, Musoke-Mudido P, Marum L, Bagenda D, Aceng E, Ndugwa C, Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children.Pediatr Infect Dis J. 1997;16:876–81.
TableCite This Article
Please use the form below to submit correspondence to the authors or contact them at the following address:
Kimberly C. Brouwer, Division of International Health and Cross-Cultural Medicine, Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Dr, MC 0622, La Jolla, CA 93093-0622, USA;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: June 29, 2010
- Page last updated: June 29, 2010
- Page last reviewed: June 29, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)